We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will ...

About a dozen lawsuits, citing 2024 studies, allege Ozempic causes a rare eye disorder that leads to irreversible blindness. ...

A grandma of 11 and a New Jersey man have joined the growing chorus of users of the wildly popular weight-loss drugs Ozempic ...

Shares of the Ozempic-maker fell while the rest of the market rose,as it's facing a hit to revenue from different directions.

The company’s blockbuster drugs helped it beat Wall Street’s expectations—while WeightWatchers declares bankruptcy. One day ...

Mukhopadhyay took Mounjaro, an antidiabetic medication also used for weight loss, and saw dramatic results—losing 15 percent ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...